William Michael Kavanaugh, CSO, Head Res.&Non-Clin. Development at CytomX Therapeutics, Inc. (CTMX), sold 96,736 shares at $24.34 ($2.4M) on 2017-10-04, disclosed to the SEC on 2017-10-06.
Open-market sale of $2.4M CTMX by CSO, Head Res.&Non-Clin. Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.34 | 48,368 | $1.2M | 50.0% |
| 2 | $24.34 | 48,368 | $1.2M | 50.0% |
| Total | $24.34 avg | 96,736 | $2.4M | 100% |